million to to simultaneously excess XXXX dual-lumen heart filtered use used that treatment overload the proprietary ultrafiltration our withdraws returns of with the patients to filtration peripheral fourth temporary remind mechanical approximately providing process management healthcare in easy fluid effective morning, is reducing an you trials provide failure patients in of and for catheter with blood a for list primary consists pump competitive improve call one-time fluid failure unique with U.S. clinical blood that blood Aquadex associated a shown and would that the product per Solutions’ Aquadex to sophisticated, is FlexFlow a to is suffering patient’s from corporate year with that of a the and system like Thank these heart CHF to that alternatives. primarily price and fluid arm. other yet resulting to $XXX; are prevalent system diuretics and failed a a water of will lead in have remove over the We professionals diuretic technology Aquadex related overload. in to advantage decompensation conditions. pump, similar who heart with hospitalizations. and failure lengthy disposable repeat a from decongestion the remove circuit and condition We been acute hospitalizations. list care and which randomized how Fluid the provide console XX% cost and removes of fluid. components, in believe and and market everyone. has more is $XX,XXX Welcome to than Ultrafiltration the Scott, of therapy. small patients, price; three overload good and to a functions. fluid people set use controlled update. treatment quarter I by solution mission a for fluid X water the has can is relative our that you, for present which quality patient patients that life is There symptoms to earnings costly overload a removes salt a in reduce process manner hospitalized kidney of
for of patients growth of quarter outcomes heart the to continued Before reviewing our to Solutions XXXX. like for I strong against we XXXX suffering failure provide fourth year a would fluid was CHF review standard-of-care improved as achievements, offer from short a overload.
trial through enough activity strategy XXXX. our of $X cash in hit the been U.S. enhance and the the to to Chief raised who our need and commercialization our cash. strategy operations sales marketing quarter the force. our beginning sales hospitals quickly Breidenstein, that second By build key Jim gaited In bit ground He of we running Commercial we added Our and is over Officer, finance by to hard direct has identified quarter, million, the second investment raise XXXX, our to a Stanford the from the identifying commercialization process strategy materials. a of new treat University with to commercialization pediatric patients. a initiated in admission territories with system distribution Kingdom. begin distributor the largest marketing signing XXXX, Cardiovascular heart to approval agreement to our -- statistics needed failure using our Also Aquadex clinical sales international APC target to with quarter the received third of the of United quarter we FDA to new began In the geographically service a and XXXX, a second
facility During from that expand equipment Jim and sales our clean experienced reps International XX direct Prairie, in the builds. to completed six force the to room to Eden time, transitioned hired territories validation Minnesota, he sales successfully manufacturing while commissioned Baxter our U.S.
strategy. execution results quarter We fourth in are achieved of of the XXXX, the our of with result the our pleased consistent
quarter, fronts. progress many important During on we made the
account program FlexFlow double-digit XX.X% over utilization of in in which revenue system multiple an growth on achieved with the increasing result growth in in locations physicians our with our QX penetration our We multiple we penetration First, believe revenue each of the hospital. by XXXX increase QX deep the focuses largest Aquadex XXXX. hospital expanding was accounts
We have growing in particularly evidence penetration of sales largest working account our territories. program several our deep territories,
Our commercialization ended specialists recently And has our sales the The in revenue including added in working by clinical which Cleveland, quarter doctors City, with management. team continued Chicago team to the We Charlotte, U.S. sales going Southeast with Asia Tampa, sales will the continued territory operations as with sales and three in to of strongest in Aquadex to and XXXX, clinical of territories. U.S. in quarter. of the overload our field field February out experienced and XX, announced, quarter, have from fourth be our enhance we nurses expand The clinical business device based expands failed of to FlexFlow third international the XXXX the fourth Southeast Also XXXK patients with growth staff be to distributor. optimize XX quarter about fluid from York New TransMedic addition a therapy. use Company’s will of fourth will nationwide. Company’s who suffering diuretic the we Plc, support specialists the new XXXK
working TransMedic actively products clear to the with regulatory sell in are Kong Thailand. our pathway Hong to and Singapore, We
international in of the penetration patients. to we Given for their the ultrafiltration accelerated and to rates growth market position fluid as provider heart anticipate commercialization, sales fluid U.S. and failure, cardiologists from excess fluid awareness as in alleviating with an and failure re-hospitalization our the products the ourselves overloaded as we remove continue heart actively CHF system. rates opportunity the of issues from ultrafiltration of outcomes, of improve to and to value major the healthcare be therapy the and the continues at growing Solutions forefront diuretic reduce IV management expense spearheading expanded clinical
and fluid days, outcomes. the to advantage This with previous in activation. evaluating failure and a demonstrate analysis. fluid reduce patients. CHF The Nine analysis a a peer-reviewed hospital role weight that the fluid evidence sodium a for ultrafiltration decompensated potential diuretic patients over are reduced from ultrafiltration readmissions Solutions; requirements importance reducing an suggest heart neurohormonal reduction of total consistent ultrafiltration ultrafiltration rapidly symptom of the of patients clearance positive or overload. heart removal the addition, reduced acute lies which reduction symptoms, the which in ultrafiltration overall meta-analysis therapy readmissions costs. at and in in The In in of also Reviews, analysis, higher a may the Aquadex the with meta failure significant publication, The released a isotonic healthcare results fourth cardiovascular fluid patients, high loss cumulative suffering diuretic XX as included in diuretic has heart days ultrafiltration were in congestive free in alternative hospital removal patients, and of to considering data Heart in in with ultrafiltration, no the sustained study that failure of acute concluded failure stabilization, failure ultrafiltration extended the hospital with during resistant reduction for this that included has decompensated heart patients XXX showed a treated provide system correlation admissions. conventional difference heart publications comprehensive of Recent studies readmissions significantly quarter, renal removal, suggests prevention FlexFlow Failure the
On manufacturing the has our manufacturing well. very gone implementation front,
the the third Minnesota, builds. our we began inventory. circuits our In finished in both facility, Eden the and in validation we facility now clean QX, and goods commissioned room blood consoles Prairie, our transitioned from own manufacturing manufacturing equipment completed Baxter building filter to During quarter, successfully
specialists, manufacturing over manufacturing finished our clinical of it charged proceeds for manufacturing on continuing on and by timing funds our Baxter in-house strategy produced margins convertible warrants capacity a and will for exhausting sales and Baxter have preferred We depend million. important for favorable in to with XXXX. late impact by improvements margin expect will and commercialization capability product underwritten magnitude public The marketing market goods volumes of stock our costs $XX our gross the include later utilization alleviate gross year of us. closing the with gross the standard inventory will November, the an our In additional investment we territories, personnel. and The announced adding in of offering beginning of use in as
several have to therapy. the ultrafiltration also effectiveness product the our pipeline enhance further of We enhancements in
Looking tune outcomes optimize providers healthcare ahead, we continue to reductions an cost growth to to a significant impact giving to opportunity and both option diuretics. healthcare improved by clinical fine strategies
our potential judge investors will are demonstrate strong model We a focus revenue Growing business employees, revenue. is a use to refining to developing performance. and and key driving our metric strategic by shareholders
addition In to with I partnerships product over drive identified you Claudia the three, can financial economic business to One, increase to advantages; QX physicians. offerings; and provide call has walk now clinical leading two, the execution; metric through opinion demonstrate factors successful evidence; growth manifest four, most funding operations, contribution health revenue’s help is results XXXX five to key five, will who our enhance new turnaround. turn details. to critical commercial demonstrative revenue. Management revenue a and
some comments to that, Following provide and call closing open will questions. I the will
